sorry, I made a mistake, it is not 37.34 euros but 73.34 euros difference of the double, again sorry, greetings from the Netherlands

this is my last post: i ordered 2 hahaha the thrifty Dutchman ???? try first, then enough time to order more, i will keep you informed how it goes, have a nice weekend everyone

I ordered them from Amazon. com and it cost me 2 pieces 37.34 euros with shipping included

i ordered 2 ActiPatch and they come in on the 18th it is that i have shares in BIEL so i know what it is but if they were hanging in a sporting goods store or in another store i wouldn't know what it is i would anyway rather buy a painkiller again because it is in your system so it will take quite a while before this really gets off the ground or there must be such a great advertising campaign, yes then ????????

I don't know but it would be good for us, the share price could be fairer I guess

tomorrow will be a beautiful day for BIEL and for us, my feeling says that because the last minutes bought a lot of shares at 0.0043 is a sign for me that tomorrow will be a beautiful day

I understand that this is not good news to read like that, but I don't understand

I think this should be brought to the attention of health insurers, they would like to make money and this would fit well up their alley, and they should bring it to the attention in Europe, now to have it come over from America every time and waiting 2 to 3 weeks also does not promote sales

also for us ))

ric, thanks for the information

good morning, I am curious about her story

I certainly have faith in BIEL and also in you who work everything out, I think that is really great to find out in such a way, thank you for that

fair is fair i bought 3 million shares ranged from 0.0037 and 0.0049 and i really don't know where this stock is going, i also can't foresee what the earnings could be for BIEL in the coming year, for me this is a gamble just because you guys are so enthusiastic

the big pharmaceutical companies will not be happy that they can no longer bring their painkillers to humans, I think

good morning, for the ladies and gentlemen who want to order a KT Recovery + Wave in EUROPE, go to Amazon.com and order an ActiPatsch, I can't wait until the 18th of March and the postman has been at the door, I have 2 ordered and shipping costs EURO 73.34, so a bargain, greetings from the Netherlands

Add 300K to 0.049 just to get it higher )

1000 x thanks, I ordered 2 from Amazon and indeed as ActiPatsch, I am already very happy with them and they still have to be shipped 03-18 I get them in ))

there is still a lot of work to be done, I wanted to order the KT Recovery + Wave but it is not yet available in all of Europe and to order it now in America I pay about $ 75, so that will not be it

would biel be a takeover candidate?

so in 2 months we will know more

I can only order the KT tape from Amazon in the Netherlands, but not the KT Recovery + wave, which is a shame, if I order it in America, it will cost almost twice as much as what it originally costs, so I just wait

I do not know yet if I did it smart but I got in with 2 million on 0.0037 and now I hope it does not go down too far

thanks for the answer plus calculation

it can go to a nickel but why don't you talk about the outstanding shares how many are there and how much does a company need to have a profit to bring this to a nickel ???

Nice

Hoppaaaaaaaaaaaa

I hardly dare to write it hahaha but good times are coming for us at RGBP, good luck almost everyone today

Great

Great

Nice

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels
PR Newswire - Fri Nov 01, 12:00PM UTC
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that suppression of NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under conditions associated with cancer and wet macular degeneration. The data, which was obtained using human umbilical vein endothelial cells (HUVEC), indicates that NR2F6 may have a larger biological role than originally suspected.

Regen BioPharma, Inc. has been utilizing NR2F6 as a target for immune modulation and cancer stem cells. To the Company's knowledge, this is the first indication to date that NR2F6 is involved in the formation of new blood vessels.

"New blood vessels are typically not formed in an adult except in conditions such as cancer (in which the tumor cells require a new blood supply) or in wet macular degeneration; a condition in which new blood vessels result in impairment of vision," said Thomas Ichim, PhD, co-inventor of the patent and consultant to the Company. "In our experiments, we observed that inhibition of NR2F6 selectively blocked multiplication of blood vessel cells that were stimulated with Vascular Endothelial Growth Factor (VEGF). Since VEGF is associated with disease conditions, it is possible that our approach possesses some degree of specificity in blocking pathological but not healthy formation of new blood vessels. New blood vessels suggests that this approach may not suppress healthy blood vessels which are primarily formed independently of VEGF."

Drugs which target VEGF as a means of suppressing pathological blood vessel formation include Avastin (Sales $2.8 Billion in 20181) for cancer and Lucentis (Sales $1.9 Billion in 20182).

"What this data demonstrates is a potential mechanism to kill cancer cells without the toxicity associated with conventional treatments," noted the Company's Chairman & CEO David Koos. "We believe this coupled with our current small molecule therapies as a quality additional approach to treating cancer."

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB:RGBP) and (OTCQB:RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

References:

1 https://www.fiercepharma.com/special-report/4-avastin

2 https://www.market-scope.com/pages/news/473/lucentis-us-sales-drop-11-percent-in-q4-2017-grow-1-percent-for-full-2017

CONTACT INFORMATIONRegen BioPharma Inc.David R. Koos, Ph.D.Chairman & Chief Executive OfficerPhone: +1-619-702-1404 Fax: +1-619-330-2328 http://www.regenbiopharma.comdavid.koos@regenbiopharma.com

https://c212.net/c/img/favicon.png?sn=IO23154&sd=2019-11-01

View original content:http://www.prnewswire.com/news-releases/regen-biopharma-inc-discovers-fundamental-role-of-nr2f6-in-production-of-malignant-blood-vessels-300949761.html

SOURCE Regen BioPharma, Inc.

https://rt.prnewswire.com/rt.gif?NewsItemId=IO23154&Transmission_Id=201911010800PR_NEWS_USPR_____IO23154&DateId=20191101

Hoppaaaaaaaaa

I have a suspicion that the news will come a little later, too bad

gint1, nothing wrong with this 8k, thumbs up

it is quiet except with the share price

it doesn't look like we are getting news today although we can still do it but normally we get the news very early or it must be so much that the computer cannot handle it ))

I nowhere read CELZ in this article and how can this actually, type 1 diabetes still has to be submitted I thought

haha Wok_asian and hankjoejr what I wrote down was a joke, because today we got good news again and the price went down hahaha sorry if you take this seriously, I am full in CELZ so no reason to talk it down

I hope it doesn't get approved by the FDA because I'm afraid it will go down even faster